Dicerna Pharmaceuticals, Inc. (DRNA) Income Statement Analysis

See more : PT Indah Kiat Pulp & Paper Tbk (INKP.JK) Income Statement Analysis – Financial Results

Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Gujarat Hy-Spin Limited (GUJHYSPIN.BO) Income Statement Analysis – Financial Results
POSCO-Thainox Public Company Limited (INOX.BK) Income Statement Analysis – Financial Results
Next 15 Group plc (NXFNF) Income Statement Analysis – Financial Results
Ash-Sharqiyah Development Co. (6060.SR) Income Statement Analysis – Financial Results
Public Joint-Stock Company “Pharmsynthez” (LIFE.ME) Income Statement Analysis – Financial Results

Dicerna Pharmaceuticals, Inc. (DRNA)

Industry: Biotechnology

Sector: Healthcare

Website: https://dicerna.com

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Metric	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	164.31M	23.90M	6.18M	2.28M	295.00K	184.00K	0.00	0.00	7.02M	7.91M
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	164.31M	23.90M	6.18M	2.28M	295.00K	184.00K	0.00	0.00	7.02M	7.91M
Gross Profit Ratio	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	0.00%	100.00%	100.00%
Research & Development	205.38M	109.34M	45.71M	36.98M	41.69M	43.97M	29.45M	11.56M	11.57M	10.71M
General & Administrative	72.13M	42.75M	21.69M	25.88M	18.35M	19.24M	15.65M	5.82M	4.70M	4.82M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	72.13M	42.75M	21.69M	25.88M	18.35M	19.24M	15.65M	5.82M	4.70M	4.82M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	277.52M	152.09M	67.40M	62.86M	60.04M	63.21M	45.10M	17.38M	16.27M	15.52M
Cost & Expenses	277.52M	152.09M	67.40M	62.86M	60.04M	63.21M	45.10M	17.38M	16.27M	15.52M
Interest Income	6.01M	7.54M	2.10M	539.00K	235.00K	188.00K	63.00K	4.00K	2.00K	3.00K
Interest Expense	20.00K	3.00K	603.00K	0.00	0.00	0.00	199.00K	952.00K	1.34M	997.00K
Depreciation & Amortization	2.22M	1.25M	774.00K	778.00K	840.00K	727.00K	848.00K	523.00K	551.00K	474.00K
EBITDA	-110.51M	-119.20M	-87.48M	-59.27M	-58.67M	-62.11M	-46.89M	-17.04M	-8.23M	-7.09M
EBITDA Ratio	-67.26%	-498.67%	-1,416.39%	-2,602.99%	-19,889.15%	-33,756.52%	0.00%	0.00%	-117.29%	-89.59%
Operating Income	-113.21M	-128.19M	-61.22M	-60.59M	-59.75M	-63.03M	-45.10M	-17.38M	-9.25M	-7.61M
Operating Income Ratio	-68.90%	-536.25%	-991.26%	-2,660.83%	-20,253.56%	-34,253.80%	0.00%	0.00%	-131.86%	-96.27%
Total Other Income/Expenses	461.00K	7.73M	-27.63M	539.00K	235.00K	188.00K	-2.84M	-1.14M	-871.00K	-943.00K
Income Before Tax	-112.75M	-120.46M	-88.85M	-60.05M	-59.51M	-62.84M	-47.94M	-18.52M	-10.12M	-8.56M
Income Before Tax Ratio	-68.62%	-503.93%	-1,438.68%	-2,637.15%	-20,173.90%	-34,151.63%	0.00%	0.00%	-144.28%	-108.19%
Income Tax Expense	481.00K	7.73M	-27.03M	539.00K	235.00K	188.00K	-2.64M	-188.00K	471.00K	54.00K
Net Income	-112.75M	-120.46M	-88.85M	-60.05M	-59.51M	-62.84M	-47.94M	-18.52M	-10.12M	-8.56M
Net Income Ratio	-68.62%	-503.93%	-1,438.68%	-2,637.15%	-20,173.90%	-34,151.63%	0.00%	0.00%	-144.28%	-108.19%
EPS	-1.51	-1.76	-1.60	-2.90	-2.87	-3.09	-2.98	-1.11	-4.95	-0.11
EPS Diluted	-1.51	-1.76	-1.60	-2.90	-2.87	-3.09	-2.98	-1.11	-4.95	-0.11
Weighted Avg Shares Out	74.52M	68.43M	55.62M	20.72M	20.72M	20.32M	16.07M	16.63M	2.05M	77.91M
Weighted Avg Shares Out (Dil)	74.52M	68.43M	55.62M	20.72M	20.72M	20.32M	16.07M	16.63M	2.05M	77.91M

Novo Nordisk to Acquire Dicerna

November 18, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi)...

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

November 12, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announces Lilly has declared proof of principle for first two targets in the companies' exclusive relationship in neurodegeneration and pain.

Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly

November 12, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Eli Lilly and Company (“Lilly”) has declared proof of principle for the first two targets in the companies’ exclusive relationship...

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

November 12, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna presented results from its Phase 1 trial of belcesiran, in development for the treatment of AATLD, at AASLD.

Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

November 12, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today presented results from its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic in development for the treatment...

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript

November 9, 2021seekingalpha.com

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript

Dicerna Pharmaceuticals (DRNA) Reports Q3 Loss, Tops Revenue Estimates

November 9, 2021zacks.com

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of 46.34% and 7.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Dicerna Pharmaceuticals: Q3 Earnings Insights

November 9, 2021benzinga.com

Dicerna Pharmaceuticals (NASDAQ:DRNA) reported its Q3 earnings results on Tuesday, November 9, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

November 9, 2021businesswire.com

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had an exciting and...